Physician organization urges the Senate to reauthorize the bill before leaving for August recess
WASHINGTON – The Alliance for Patient Access (AfPA) made the following statement about the FDA Reauthorization Act of 2017 (S. 934), which updates the Prescription Drug User Fee Act (PDUFA), a critical component of the approval of new, groundbreaking therapies.
STATEMENT FROM BRIAN KENNEDY, EXECUTIVE DIRECTOR, ALLIANCE FOR PATIENT ACCESS:
“The Prescription Drug User Fee Act is critical to the approval of new medications in the development pipeline. PDUFA provides additional resources that FDA uses to increase its capacity to review and approve new therapies.
“Patients have benefited because of PDUFA and that must continue, uninterrupted. Any disruption to PDUFA will seriously jeopardize the years of work done to bring new, groundbreaking and life-changing therapies to patients.
“We urge the Senate to prioritize patients’ needs by swiftly passing the FDA Reauthorization Act of 2017 before August break.”
For more information about the importance of PDUFA to patient access, view this video.
The Alliance for Patient Access is a national network of physicians dedicated to ensuring patient access to approved therapies and appropriate clinical care.